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Abstract
Injection of AAV into the cerebrospinal fluid (CSF) offers a means to achieve widespread 
transgene delivery to the central nervous system, where the doses can be readily translated from 
small to large animals. In contrast to studies with other serotypes (AAV2, AAV4, AAV5) in 
rodents, we report that a naturally-occurring capsid (AAV9) and rationally-engineered capsid 
(AAV2.5) are able to achieve broad transduction throughout the brain and spinal cord parenchyma 
following a single injection into the CSF (via cisterna magna or lumbar cistern) in non-human 
primates (NHP). Using either vector at a dose of ~2×1012 vg per 3-6 kg animal, approximately 2% 
of the entire brain and spinal cord was transduced, covering all regions of the CNS. AAV9 in 
particular displayed efficient transduction of spinal cord motor neurons. The peripheral organ 
biodistribution was highly reduced compared to intravascular delivery, and the presence of 
circulating anti-AAV neutralizing antibodies up to a 1:128 titer had no inhibitory effect on CNS 
gene transfer. Intra-CSF delivery effectively translates from rodents to NHPs, which provides 
encouragement for the use of this approach in humans to treat motor neuron and lysosomal storage 
diseases.
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INTRODUCTION
Recently, the adeno-associated virus (AAV) serotype 9 capsid was identified as a vector 
capable of transducing neurons and glia throughout the CNS following intravenous delivery 
in adult rodents, cats, and NHPs [1-5]. However, the translational feasibility of an 
Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
Correspondences should be addressed to Steven J Gray, graysj@email.unc.edu, Phone: (919) 966-0905, Fax: (919) 966-0907. 
CONFLICT OF INTEREST
The authors declare no conflict of interest.
SUPPLEMENTAL INFORMATION
Supplementary information is available at Gene Therapy’s website
HHS Public Access
Author manuscript
Gene Ther. Author manuscript; available in PMC 2013 October 01.
Published in final edited form as:













intravascular delivery approach for CNS disorders is problematic due to the high doses 
required, high biodistribution to peripheral tissues, reduced efficiency for CNS transduction 
in NHPs, and strong inhibition by low levels of circulating anti-AAV9 neutralizing 
antibodies (NAbs) [3]. Intracerebroventricular injection of AAV into the CSF has been 
utilized as an alternative approach to transduce the brain, but previously tested AAV 
serotypes (2, 4, and 5) are not able to efficiently penetrate into the brain parenchyma and 
transduce neurons without adjuvants such as mannitol; instead, AAV 4 and 5 efficiently 
transduce the ependymal cells that line the ventricles [6-8].
Intrathecal injection into the lumbar cistern or injection into the cisterna magna have been 
utilized as alternative approaches to deliver AAV to the central and peripheral nervous 
systems via the CSF. Although these studies have been conducted in rodents with AAV1, 
AAV2, AAV3, AAV5, AAV6, AAV8, and AAV9, the primary focus has been on spinal 
cord and/or DRG transduction. Conversely, in rodents intrathecal AAV delivery produces 
only minimal brain transduction [9-14]. For AAV9, transduction of the spinal cord in mice 
was reportedly efficient but mostly limited to the lower thoracic and lumbar spinal cord [13]. 
In contrast, when pigs received intrathecal injection of AAV9, the transduction pattern could 
be diffusely spread across the entire spinal cord if a catheter was used to inject the vector 
into the CSF directly at the cervical, thoracic, and lumbar regions [15]. Interestingly and in 
contrast to the results in mice, in the pigs there was a high degree of brain transduction 
present regardless of whether the vector was injected diffusely across the spinal cord or just 
in the lumbar cistern (S. Gray, unpublished observation). Very recently, Samaranch et al 
[5]reported that injection of AAV9 into the cisterna magna of NHPs resulted in widespread 
brain transduction similar to intravascular delivery. These studies suggest that injection into 
CSF allows diffuse delivery to large areas of the brain and spinal cord where the doses can 
be realistically scaled to larger animals and humans.
In this study, we sought to explore the translational potential of intra-CSF delivery of AAV 
for spinal cord and brain transduction. Based on previously published results [5, 13, 15, 16] 
and those presented here, AAV2.5 and AAV9 are capable of intraparenchymal neuronal 
transduction following intra-CSF delivery. AAV9 and AAV2.5 were compared 4 weeks 
following injection into the cisterna magna in NHPs, then compared to AAV9 injected into 
the lumbar intrathecal space. We assessed variables critical for the translation of this 
approach to humans, including the efficiency of brain and spinal cord transduction, dose 
response, biodistribution to peripheral organs, and evasion of naturally-occurring NAbs to 
the vector.
RESULTS
AAV2.5 is an engineered version of AAV2 that allows transduction of neurons in the brain 
parenchyma following intra-CSF injection
Following injection of AAV vectors into the ventricles of the brain, natural serotypes of 
AAV have only been successful at transducing ependymal cells lining the ventricles rather 
than neurons within the brain parenchyma [6]. AAV2.5 is a hybrid of AAV2 and AAV1, 
incorporating 6 amino acids from AAV1 into the AAV2 capsid [17]. These mutations confer 
enhanced muscle tropism to AAV2.5, and this capsid was used in a clinical trial for 
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Duchenne’s Muscular Dystrophy [17]. AAV2.5 (10 uL, 6.6×1010 vg), was injected into the 
anterior portion of the right lateral ventricle of adult rats in order to investigate the potential 
to transduce neurons following intra-CSF administration. Two weeks later, the rats were 
perfused, and tissue sections were taken through the entire rostral-caudal extent of the brain 
for immunohistochemistry (IHC) and immunofluorescence (IF). As seen in Figure 1, 
substantial transduction was found in the hypothalamus along the extent of the third 
ventricle, as well as in the central gray surrounding the Sylvian aqueduct. Furthermore, 
extensive transduction was found in the subcommissural organ, located within the dorsal 
third ventricle (Supplemental Figure 1), while some GFP positive vestibular neurons were 
found near the fourth ventricle. Importantly, in our previous unpublished studies, this ability 
to transduce distal structures along the ventricular system was not seen with AAV2, AAV5, 
or AAV9 (for AAV9, see supplemental Figure 2).
Injection of AAV9 or AAV2.5 into the cisterna magna of NHPs results in widespread 
transduction of the entire brain and spinal cord
AAV2.5 showed a unique characteristic that separates it from known naturally-occurring 
AAV capsids; namely, it can cross the ependymal cell barrier and transduce neurons in the 
CNS following intra-CSF delivery. In our previous studies, AAV9 showed superior ability 
in transducing the spinal cord following intrathecal delivery in mice and pigs (Supplemental 
Figure 3 and [13, 15]). To compare the potential value of these vectors for gene delivery in 
human applications, we evaluated AAV2.5 and AAV9 in cynomolgus monkeys, when 
injected into the CSF of the cisterna magna. Table 1 provides a summary of all the NHPs 
used in this study. Two NHPs were injected with scAAV2.5 (2×1012 vg) and two with 
scAAV9 (1.83×1012 vg) in 1.5 mL of PBS containing 5% sorbitol. For direct comparison of 
the intracisternal versus intrathecal routes, 2 additional animals were injected via the lumbar 
cistern with scAAV9 (1.83×1012 vg in 1 mL). After 4 weeks the animals were sacrificed. 
Serum samples were analyzed for the prevalence of neutralizing antibodies against the 
injected capsid, at the time of injection and at the time of sacrifice (Table 2). All animals 
showed a rise in NAbs of the injected serotype after 4 weeks. After 4 weeks, two animals 
(101 injected with AAV9 and 104 injected with AAV2.5) produced NAbs against the other 
serotype while 2 animals (102 and 103) did not. The native GFP fluorescence signal was not 
reliably or readily detectable, so IHC was used to enhance the signal. GFP expression in the 
brain, spinal cord, and DRG was visualized and quantified by IHC, and vector 
biodistribution throughout the spinal cord and major peripheral organs was assessed by 
qPCR (Figure 2). The specificity of the IHC was validated by performing parallel IHC on 
uninjected NHP samples, on the injected NHP samples without addition of the primary anti-
GFP antibody, and on injected versus uninjected rat brains (Supplemental Figure 4). The 
location of the coronal sections portrayed in Figure 2 is shown in Supplemental Figure 5. 
For the most part, AAV2.5 and AAV9 performed in a roughly equivalent manner throughout 
the brain and spinal cord, transducing a similar amount of tissue. The biodistribution data 
favored AAV2.5, which had approximately a 100-fold lower distribution to the spleen 
compared to AAV9. Both animals injected with AAV2.5 had pre-existing NAbs against the 
AAV2.5 capsid (1:8 and 1:128), so this could have affected the biodistribution of the vector 
to peripheral organs.
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The 2 NHPs injected via the lumbar cistern, for the most part, were comparable to these 
receiving an intracisternal injection. However, unlike the pattern seen following 
intracisternal injection, the DRG were highly transduced with approximately 15-20% of the 
area positive for GFP expression.
Intrathecal injection of AAV9 avoids pre-existing NAbs and transduces DRG at a higher 
efficiency than intracisternal injection
Our previous studies in mice by intrathecal injection showed that AAV9 was considerably 
better at transducing motor neurons than AAV2.5 ([13] and data not shown). For several 
disease applications (such as Spinal Muscular Atrophy, Giant Axonal Neuropathy, and 
Amyotrophic Lateral Sclerosis), motor neuron transduction is likely to be an important 
criteria for selecting the best vector, so we conducted further tests on AAV9 in NHPs to 
determine the translational feasibility of its use as a gene therapy vector. To test the efficacy 
of intrathecal gene transfer (relative to intracisternal) in a non-human primate model, 6 
cynomolgus monkeys were injected with 1.83×1012 vg of scAAV9/GFP vectors in 1 mL of 
1x PBS containing 5% sorbitol. In order to investigate a possible dose-response relationship, 
an additional 2 animals were injected with 5.5×1012 vg of the same vector, in 1 mL of PBS 
containing 5% sorbitol. All animals were pre-screened for NAbs against AAV9, and 2 of the 
“low dose” animals were specifically selected because they had naturally-occurring NAb 
titers of 1:32 and 1:128 (Table 2). The animals were sacrificed after 4 weeks. Serum samples 
were analyzed for prevalence of neutralizing antibodies against the injected capsid at the 
time of injection and at the time of sacrifice. Two of the animals had tested negative for 
NAbs in the prescreen 2 months prior to injection, but had (1:4 and 1:8) titers of NAbs at the 
time of injection. CSF was collected from the cisterna magna at the time of injection, 2 
hours post-injection, and at the time of sacrifice in order to check for neutralizing factors in 
the CSF before and after injection, as well as to assess the persistence of the vector at 2 
hours post-injection (Table 2). We found that at pre- and post-injection time points the CSF 
did not contain any factors that inhibited AAV transduction, except in one animal at the 4 
week time point (1:4 dilution). This animal (202) had the highest pre-existing NAb titer 
(1:128) and an even higher titer (1:1024) at 4 weeks following injection. NHP 202 had a low 
but detectable amount of NHP DNA in the 4 week CSF sample, indicating some blood 
contamination of the collected CSF, which could explain the presence of NAbs in the CSF 
(See Supplemental Table 1). All animals examined had virtually no vector remaining in 
circulation in the CSF at 2 hours post-injection, at least in the cisterna magna (Table 2).
GFP expression in the brain, spinal cord, and DRG was visualized and quantified by IHC, 
and vector biodistribution throughout the brain, spinal cord, DRG, and major peripheral 
organs was assessed by qPCR. For most of the animals (3 low dose NAb+, 1 low dose 
NAb-, 2 high dose), IHC was performed on the liver and spleen to assess vector expression 
in these peripheral organs. To broadly compare how the experimental variables affected 
gene expression in an unbiased and quantitative manner, anti-GFP IHC was done on 5-7 
micron sections from all samples and subjected to automated morphometric analysis to 
assess gene expression throughout the brain, spinal cord, DRG, optic nerve, liver, and spleen 
(Figure 3A and supplemental table 2, locations of coronal sections shown in supplemental 
table 6). Both the gray and white matter showed expression of GFP that was not evident in 
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sections prepared in parallel without the primary anti-GFP antibody or on naïve tissue 
(Supplemental Figure 4). The percent area of each slice that is GFP positive does not 
necessarily correlate to the percentage of cells transduced. In all, we found no difference in 
the distribution of CNS or peripheral organ GFP expression between any groups, regardless 
of the presence of anti-AAV9 NAbs or the vector dose. The distribution of GFP expression 
was fairly even across the entire brain and spinal cord, with an average value of 
approximately 2% of the area positive for GFP in any given region of the CNS. The vector 
DNA biodistribution mostly followed the same pattern as GFP expression, with a few 
notable exceptions (Figure 3B). The spinal cord had more vector genomes than the brain, 
and these levels were comparable to the DRG except in the high dose group where the DRG 
were at least 10-fold higher. When compared to intravascular delivery of AAV9 [3], 
intrathecal delivery resulted in a much lower proportion of vector genomes in peripheral 
organs compared to the CNS. While high levels of vector genomes were detected in the 
liver, the presence of vector genomes did not correlate with a large portion of the liver being 
positive for GFP expression. Similarly, although over 50 times more vector genomes were 
detected in the spleen than the brain, only approximately 2-5% of the spleen was positive for 
GFP expression. Interestingly, the presence of pre-existing AAV9 NAbs did not correlate 
with lower biodistribution to peripheral organs.
To illustrate how the “percent of area GFP-positive” correlates to the percentage of positive 
cells, sample images of those used for the quantitative IHC portrayed in Figure 3A are 
provided in Figure 4 (spinal cord, DRG, liver, and spleen) and Figure 5 (brain). Manual 
counting of GFP-positive versus -negative cells was done across animals 201-206, focusing 
on specific brain and spinal cord structures, and this information is provided in Table 3 with 
representative photographs of each region provided in supplemental figure 7. Although there 
were modest differences in the overall transduction efficiency of specific brain structures, all 
areas were transduced regardless of their proximity to the CSF.
In the ventral horn of the spinal cord, an abundance of large diameter (25-50 micron) cells 
were GFP-positive, indicating efficient transduction of motor neurons. This is confirmed by 
the colocalization of GFP and ChAT seen in Supplemental Figure 8. Consistent with 
previous reports [5], we observed transduction of both neurons and astrocytes throughout the 
brain and spinal cord (Supplemental Figures 9 and 10). A similar degree of spread 
throughout the brain parenchyma, along with transduction of neurons and glia, was observed 
in mice (Supplemental Figure 3). Interestingly, in some sections we captured part of the 
choroid plexus within the lateral ventricle (Figure 6). The choroid plexus was very strongly 
GFP positive, in stark contrast to the lack of GFP expression in the ependymal cells that line 
the ventricles.
DISCUSSION
Based on our results, we conclude that intra-CSF administration of AAV9 or AAV2.5 
vectors (via lumbar cistern or cisterna magna) offers a viable, translational option for global 
CNS gene delivery. Importantly, these studies appear to have a marked improvement in 
overcoming previously identified translational barriers, such as inhibition by pre-existing 
NAbs, high peripheral organ biodistribution, reduced efficiency of CNS transduction in 
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NHPs compared to rodents, and high dosage requirement [3]). It should be noted, however, 
that intrathecal administration, especially for AAV9, did not completely restrict the vector 
within the CNS. The additional success of AAV2.5 in this approach also demonstrates the 
ability to rationally engineer improved functionality into the AAV capsid for novel clinical 
applications. If very high titers of NAbs can inhibit the transduction of AAV9 after intra-
CSF delivery, as the results of Samaranch et al suggest [5], the availability of 2 distinct 
AAV serotypes capable of widespread CNS transduction would allow treatment of patients 
with high levels of NAbs against one of these serotypes (but not both). Two out of 4 animals 
showed a lack of NAb cross-presentation between AAV2.5 and AAV9 (Table 2), suggesting 
the possibility of a second administration of vector in some populations if the serotype 
capsid was switched on the second administration.
Evasion of anti-AAV neutralizing antibodies is an important consideration for any 
translational approach, since an estimated 33.5% of the human population are seropositive 
for AAV9 [18]. In this study and others, we have screened a total of 35 randomly selected 
naïve NHPs for anti-AAV9 NAbs, and the highest titer detected was 1:128. Although 
Samaranch et al. reported that anti-AAV9 serum NAb titers ≥1:200 inhibited CNS gene 
transfer when AAV9 was injected via the cisterna magna[5], in the present studies we found 
that anti-AAV serum NAb titers up to 1:128 had no inhibitory effect on successful CNS 
gene transfer. No inhibitory factors were identified in the CSF prior to vector delivery or at 4 
weeks post-injection, even when post-injection serum NAb titers rose as high as 1:2048. 
Previously, we found that a 1:4 NAb titer was sufficient to completely inhibit AAV9 
transduction of the CNS and peripheral organs if an intravascular route of administration 
was used [3]. Although the results of Samaranch et al. indicate that high serum NAb titers 
can negatively influence intra-CSF gene transfer, our results clearly show that lower NAb 
titers (that would block intravascular gene delivery) are well tolerated. Moreover, our 
limited survey of pre-existing NAb levels in NHP would suggest that the presence of 
naturally-occurring NAbs at levels inhibitory to intra-CSF vector administration would be 
rare. The methods of titering the NAbs were different in these studies, so we cannot 
comment on what level of NAb would be inhibitory in relation to our study.
This NHP study yielded some notable differences compared to previous intrathecal AAV9 
delivery studies in mice and pigs [13, 15]. In pigs, the vector distribution was mostly limited 
to the lumbar spinal cord unless a catheter was manipulated to physically distribute the 
vector to the cervical and thoracic regions. However, in NHPs, a single bolus injection at the 
lumbar region provided a relatively even level of transduction to the entire spinal cord and 
brain. Although no clear explanation exists, differences in size, anatomy, and species must 
be considered. For example, unlike humans and monkeys the pig epidural space contains 
fatty deposits that may restrict CSF flow [19]. In pigs, the biodistribution to peripheral 
organs was barely detectable, whereas in NHPs the vector was detected in the liver and 
spleen at levels that equaled or exceeded levels seen in the CNS. Also, the CSF and CNS 
volumes across species and age does not always correlate with overall body size, so 
comparing “equivalent” doses across species becomes a matter of which metric is used for 
scaling. In our case, we utilized CSF volume as our comparative metric, assuming 
equivalent CSF volumes of 0.035 mL in mice, 0.09 mL in rats, 20 mL in pigs, 12-15 mL in 
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NHPs, and 140 mL in humans [20-22]. In this case, the high dose in the referenced pig study 
(~1.5×1011 vg per mL of CSF) [15] is equivalent to the low dose used in the present study in 
NHPs (~1.5×1011 vg per mL of CSF). Again, it is unclear whether the increased peripheral 
biodistribution in NHPs compared to pigs is the result of physiological/anatomical 
differences, differential receptor biology and binding kinetics of AAV9, or differences in the 
injection protocol that could have led to vector leakage. Previous studies have indicated that 
IT delivery in mice may restrict the vector to the lower spinal cord, although these studies 
were done with a lower AAV titer [23]. However, our present results show a similarity in 
the CNS and peripheral biodistribution between mice and NHPs receiving intrathecal 
injections at equivalent doses (scaled by CSF volume), including transduction throughout 
the brain (Supplemental Figure 3). The roughly equivalent translation of the intrathecal 
approach between mice and NHPs is in contrast to an IV approach, which works 
considerably better in mice than NHPs [3].
A confusing observation from our rodent studies was the lack of widespread transduction 
following intraventricular injection of vector, whereas injections into the lumbar cistern 
produced widespread CNS transduction (Supplemental Figures 2 and 3). Since CSF flows in 
the direction from the lateral ventricles to the lumbar cistern, it wasn’t clear why the lateral 
ventricle injection didn’t work. A possible explanation is that AAV9 has a very high affinity 
for the ependymal cells of the choroid plexus, supported by the very strong transduction of 
this structure that we observed in the NHPs (Figure 6). Injection into the lumbar cistern 
allows the vector to circulate in the CSF before contacting the choroid plexus, whereas 
injection into the ventricles would concentrate the AAV9 vector around those cells from the 
moment of injection. Transduction of the choroid plexus itself could be beneficial in certain 
therapeutic applications, since these cells would be ideal “factories” to secrete factors into 
the CSF. However, the turnover of these cells would likely undermine long-term persistent 
transgene expression from the choroid plexus, since AAV genomes don’t normally persist in 
dividing cell populations.
Several factors should be considered in order to achieve efficient, global CNS gene transfer 
with AAV9. First, the present studies exclusively employed self-complementary AAV 
vectors, which have at least a 20-fold advantage over traditional single-stranded vectors in 
terms of transduction efficiency [3, 24, 25]. Since these studies utilized self-complementary 
AAV vectors, this would limit the entire gene expression cassette (minus ITRs) to 
approximately 2.1 kb. Larger gene cassettes (up to approximately 4.6 kb) could be packaged 
in single-stranded vectors, but a larger dose would likely be required to compensate for the 
lower efficiency of traditional single-stranded AAV vectors. In the present study, we used a 
hyperosmolar buffer composed of PBS containing 5% sorbitol, which is a common AAV 
storage buffer to prevent vector aggregation and possible precipitation at higher 
concentrations. The volume of the injection was low (1 mL compared to a normal CSF 
volume of ~12-15 mL in a NHP), so only a small and transient overall change in the overall 
CSF osmolarity would be expected, but we cannot exclude the possibility that this affected 
the biodistribution in some way. In our previous study on intravascular AAV9 delivery to 
the CNS in NHPs, we used a dose of ~9×1012 vg/kg (~3-4×1013 vg per animal) [3]. Our 
present intra-CSF study used a low dose of 1.8×1012 vg (approximately 6×1011 vg/kg or 
1.5×1011 vg per mL CSF) per animal and a 3-fold higher dose of 5.5×1012 vg per animal. 
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Interestingly, we did not see an increase in transduction efficiency between our low and high 
dose intrathecal groups, which may suggest that our low dose is already a saturating dose for 
AAV9 under the present study parameters. However, with the low number of high dose 
animals (n=2) we cannot draw any firm conclusions. It is entirely possible that a lower dose 
could provide a similar level of transduction, but there remains the need for new vector 
development to increase the transduction efficiency beyond the “saturated” capabilities of 
AAV9. Samaranch et al. concluded that intravascular and intracisternal AAV9 transduction 
was equivalent[5], but they were using a higher intravascular dose of 3×1013 vg/kg and if 
the intra-CSF dose (1.8×1013 vg/kg) was already past saturated levels then their study may 
have missed the transduction advantage that intra-CSF delivery provides at lower doses. 
Based on our results, we conclude that AAV9 intrathecal delivery is superior to 
intravascular delivery to achieve global CNS transduction, both in terms of transduction 
efficiency and lack of translational barriers.
In summary, we conclude that AAV9 and AAV2.5 can be delivered in a NHP by intra-CSF 
injection to globally deliver a transgene to the entire CNS. Intrathecal injections are routine 
non-surgical procedures that are often done in an outpatient setting with minimal risk. This 
approach has strong translational implications for lysosomal storage diseases, or any other 
approach in which a secreted gene product is utilized. The efficiency of spinal cord 
transduction would also suggest feasible applications for motor neuron diseases such as 
spinal muscular atrophy, giant axonal neuropathy, and amyotrophic lateral sclerosis.
MATERIALS AND METHODS
Virus preparation
Recombinant AAV vectors were generated using HEK293 cells grown in serum-free 
suspension conditions in shaker flasks, using proprietary methods developed at the UNC 
Gene Therapy Center Vector Core facility. In brief, the suspension HEK293 cells were 
transfected using polyethyleneimine (Polysciences) with the following helper plasmids 
(pGSK2/9 or pXR2.5, and pXX6-80 [26]) plus the ITR-flanked transgene construct pTRS-
KS-CBh-EGFP (referred to throughout this manuscript as GFP) [16], to generate self-
complementary AAV vectors. Forty-eight hours post-transfection, cell cultures were 
centrifuged and supernatant was discarded. The cells were resuspended and lysed through 
sonication as described [27]. 550 Units of DNase was added to the lysate and incubated at 
37°C for 45 minutes, followed by centrifugation at 9400 × g to pellet the cell debris and the 
clarified lysate was loaded onto a modified discontinuous iodixanol gradient followed by 
column chromatography. Purified vectors were dialyzed in 1x PBS containing 5% D-
sorbitol. Titer was obtained by dot blot [27].
Rodent Studies
Animals were maintained in a 12 hour light-dark cycle and had free access to food and 
water. All care and procedures were in accordance with the Guide for the Care and Use of 
Laboratory Animals (DHHS Publication No. [NIH] 85-23), and all procedures received prior 
approval by the University of North Carolina Institutional Animal Care and Usage 
Committee.
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For AAV infusions into the brain, rats (pathogen-free male Sprague-Dawley rats obtained 
from Charles Rivers, N=3) first were anesthetized with a 50 mg/kg i.p. dose of pentobarbital 
and placed into a stereotaxic frame. Using a 32 gauge stainless steel injector and a Sage 
infusion pump, the rats received 10μL of single stranded AAV 2.5 (6.6 × 1010 vector 
genomes) over 10 minutes into the right lateral ventricle (0.6mm anterior to Bregma, 1.2 
mm lateral, 4.0 mm vertical, according to the atlas of Paxinos and Watson [28]). The 
injector was left in place for 3 minutes post-infusion to allow diffusion from the injectors. In 
all cases, the incision was sutured, and the animals were allowed to recover for 14 days. 
Two weeks after ventricular AAV administration, the rats received an overdose of 
pentobarbital (100 mg/kg pentobarbital, ip) and were perfused transcardially with ice-cold 
100 mM sodium phosphate-buffered saline (PBS, pH 7.4), followed by 4% 
paraformaldehyde in PB (pH 7.4).
Mouse IT injections were done in 8-12 week-old female BALB/c mice weighing 
approximately 20 grams, purchased from Jackson Laboratory (Bar Harbor, ME). Five μL of 
the vector solution (8.75×109 or 1×1010 total vg per mouse) was injected into the IT space of 
the lower lumbar cord in a non-sedated mouse, as described in [29]. For IT delivery, 
scAAV9 vector was prepared in a vehicle solution containing 10-12.5% lidocaine-HCl (MPI 
Biomedicals, Solon, OH) in 1×PBS + 3.75% sorbitol. Needle penetration into the IT space 
was indicated by a tail flick, then successful injections were confirmed by transient (10-15 
min.) bilateral paralysis of the hindlimbs from the lidocaine [30]. Animals that did not 
receive a successful injection were removed from the study. Mixing AAV2 with lidocaine 
did not affect its transduction of HEK293 cells, and injecting AAV9 into mice (IT) without 
lidocaine did not alter the transduction pattern (data not shown). At termination, the mice 
were transcardially perfused with PBS containing 1U/mL heparin (Abraxis Pharmaceutic 
Products, Shaumburn, IL).
Quantitative PCR and biodistribution
Quantitative PCR (qPCR) was used for vector biodistribution studies. Tissue DNA was 
purified and quantitated as described [3]. Data is reported as the number of double-stranded 
GFP DNA molecules per 2 copies of the monkey GAPDH locus, or in other words the 
number of vector DNA copies per diploid NHP genome.
Immunolabeling and imaging of samples (rodent samples)
After 48 hours of fixation in PBS with 4% paraformaldehyde, tissue samples were sectioned 
at 40 microns using a Leica vibrating microtome at room temperature. To enhance the signal 
observed with GFP, immunohistochemistry (IHC) was performed. Samples were incubated 
for 1 hour at room temperature in blocking solution (10% goat serum, 0.1% triton X-100, 
1X PBS), then incubated 48-72 hours at 4° C in primary antibody solution (3% goat serum, 
0.1% triton X-100, 1X PBS, rabbit anti-GFP [Millipore # AB3080, 1:500]). After washing 3 
times in 1X PBS, secondary amplification was performed using a VectaStain ABC Elite Kit 
(Vector Labs, #PK-6101) with 3,3′-diaminobenzidine tetrachloride (DAB; Polysciences, Inc. 
#04008) substrate and nickel-cobalt intensification of the reaction product.
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For immunofluorescence (Supplemental Figure 1), sections were incubated with a 
monoclonal antibody to Nestin (1:1000; Chemicon). Following incubation for 48 hrs, the 
sections were rinsed with PBS and blocked again for 30 minutes at room temperature in PBS 
containing 10% goat serum. Sections were then incubated for 45 min at 4°C with Alexafluor 
594-conjugated goat anti-mouse IgG (1:500, Invitrogen) in PBS containing 3% goat serum. 
Rinsed sections were mounted and fluorescence was visualized by confocal microscopy.
Microscopy
DAB-processed brain sections were digitized using a Scan-Scope slide scanner (Aperio 
Technologies, Vista, CA). Virtual slides were viewed using ImageScope software package 
(v. 10.0; Aperio Technologies), and images were generated using the same software. For 
immunofluorescence studies, colocalization with native GFP fluorescence was determined 
from a minimum of five consecutive steps in a Z-series taken at 1 μm intervals through the 
section of interest using a 40x objective.
NHP Studies
Animals, surgeries, necropsy, and tissue processing (performed by MPI 
Research)—NHP studies were conducted on a contractual basis by MPI Research 
(Mattawan, MI), in accordance with NIH guidelines and approved by their Institutional 
Animal Care and Use Committee. Male cynomolgus macaques (Macaca fascicularis) were 
used, with weights and ages provided in Table 1, and all study animals received standard 
housing and care. For injections into the cisterna magna, the animals were sedated with 
ketamine and the back of the head was shaved for access to the cisterna magna. The animal 
was placed in lateral recumbence and the head was tilted forward. The cisterna magna was 
accessed using an over-the-needle catheter and placement was verified by the presence of 
cerebral spinal fluid (CSF). The animal was slowly infused with 1.5 mL of vector, followed 
by a flush of 0.2 mL of sterile saline. The needle was removed and the animal was allowed 
to recover normally. For lumbar intrathecal injections, each animal was sedated, placed on 
its stomach, a small skin incision made over L3-L4, and a 22 gauge spinal needle introduced 
into the intrathecal space using clean technique. Placement of the needle was verified by 
fluoroscopy. The vector (1 mL) was slowly injected by hand, the needle withdrawn, and the 
incision site closed. Each animal was maintained in a ventral recumbancy until recovered 
from anesthesia. In all experiments, subjects were sacrificed at 4 weeks post-injection and 
perfused with PBS. Serum samples were collected prior to injection and at the time of 
sacrifice. CSF samples were collected just prior to injection, 2 hours post-injection, and at 
the time of sacrifice.
At sacrifice, samples of the liver, spleen, kidney, heart, lung, and testis were collected. For 
the intracisternal injections and intrathecal animals 303 and 304, the brain was divided into 6 
coronal blocks (see supplemental figure 5) and samples from each block were sectioned at 
5-7 microns on a cryostat. Sections from the cervical, thoracic, and lumbar spinal cord and 
DRG were also collected. These sections were subjected to IHC against GFP (or with no 
primary antibody as a control) for gene expression analysis. Conditions were optimized so 
that IHC performed on naïve animal tissue showed no background staining; positive and 
negative control images are provided in supplemental figure 4. In each sample 7 random 
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fields were selected for histomorphometric analysis of the percentage of the area that was 
positive for GFP, in order to provide an unbiased quantification of the gene expression 
biodistribution. For the follow-up intrathecal studies, the same samples were collected 
except the brain was divided into 5 coronal blocks (see supplemental figure 6) and the optic 
nerve was also collected. Brain, spinal cord, DRG, optic nerve, liver, and spleen sections 
were collected and subjected to IHC against GFP and histomorphometric analysis on 2 
random fields, as was done for the 4 animals injected into the cisterna magna. These IHC 
and histomorphometric studies were done by MPI Research (Mattawan, MI). Samples from 
the identical regions on the contralateral side were sent to UNC for biodistribution analysis.
The above mentioned samples stained for GFP were used for quantification of GFP-positive 
cells in specific brain areas. An inverted Leica DMIRB microscope with a color 
Micropublisher camera was used to generate the images at an objective of 20X 
(Supplemental Figure 7). The number of GFP-positive brown (DAB) cells, as well as the 
total number of blue (cresyl violet) nuclei, were manually counted and the percentage of 
GFP positive cells for each brain region was calculated.
In order to perform cellular identification of the GFP-transduced cells, 40 microns brain 
sections were incubated at 4 degrees in PBS-T (1× PBS + 0.1% Triton X-100) containing 
3% serum and a rabbit anti-GFP (1:500 Millipore AB3080), mouse anti-GFAP (1:1000 
Sigma 032M4779) or mouse anti-NeuN (1:500 Millipore MAB377). Forty-eight hours post 
incubation; these samples were washed in PBS-T and incubated with Alexafluor 488-
conjugated goat anti-rabbit IgG (1:2000 Invitrogen A11008) and Alexafluor 594-conjugated 
goat anti-mouse IgG (1:2000 Invitrogen A11032). Forty micron spinal cord sections were 
incubated with a rabbit anti-GFP (1:500) antibody and a goat anti-ChAT (1:1000 Millipore 
AB144P) primary. These samples were washed and incubated with Alexafluor 488-
conjugated donkey anti-rabbit (1:2000 Invitrogen A21206) and Alexafluor 594-conjugated 
donkey anti-goat IgG (1:2000 Invitrogen A11058). Both brain and spinal cord samples were 
washed and mounted onto slides, visualized on a Leica SP2 Confocal microscope with a 
20X objective. Each image is merged from at least 5 serial Z-stacks. Unstained brain and 
spinal cord sections at 40 microns were mounted onto slides for native GFP visualization.
NHP neutralizing antibody titer
NHP neutralizing antibody titer was determined exactly as described [3]. The neutralizing 
antibody titer reported is the serum or CSF dilution showing a 50% decrease in the 
transduction of Hela RC32 cells.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. AAV2.5 can cross the ependymal cell barrier and transduce neurons after ventricular 
administration
AAV2.5/GFP (10 uL, 6.6×1010 vg) was injected into the anterior portion of the right lateral 
ventricle of adult rats, and after 2 weeks gene expression was assessed by anti-GFP IHC. (A) 
Transduction of cells with neuronal morphology in the hypothalamus along the third 
ventricle. (B) GFP-positive cells with neuronal morphology in the dorsal central gray. Scale 
bar is 50 microns.
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Figure 2. Comparison of AAV9 and AAV2.5 transduction after intracisternal administration in 
NHPs, versus AAV9 intrathecal administration
scAAV9 or scAAV2.5 vectors were injected into the cisterna magna (IC) or lumbar 
intrathecal space (IT) of NHPs, and the animals were sacrificed 4 weeks later. (A) Five to 
seven micron sections from the brain, spinal cord, and DRG were subjected to IHC against 
GFP, then quantified by histomorphometry. For the location of brain samples 1-6, see 
supplemental figure 5. (B) Total DNA was purified from the samples, and the copies of GFP 
relative to the NHP GAPDH locus were ascertained by qPCR. C = cervical, T = thoracic, L 
= lumbar, ND = no data. The legend for both panels is provided in (A).
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Figure 3. Intrathecal AAV9 injection in NHPs provides widespread CNS transduction with 
reduced peripheral biodistribution and evasion of NAbs
NHPs received a single intrathecal injection of 1.83×1012 vg (low dose) or 5.5×1012 vg 
(high dose) scAAV9/CBh-GFP. Four weeks later, the animals were sacrificed and the 
indicated samples from the CNS and peripheral organs were processed. (A and B) Samples 
were sectioned at 5-7 microns and subjected to IHC against GFP with histomorphometric 
quantification of GFP expression. (C) Total DNA was purified from the samples, and the 
copies of GFP relative to the NHP GAPDH locus were ascertained by qPCR. All brain 
measurements are the average of all quadrants per block analyzed. For the location of brain 
samples 1-5 and individual data points, see supplemental figure 6 and supplemental table 2. 
Brain IHC for animals 303 and 304 examined slightly different brain areas, so this data is 
portrayed only in Figure 2. C = cervical, T = thoracic, L = lumbar. Asterisks indicate tissues 
where a sample from only 1 animal was tested. NAb+ = NAb titer >1:2, and NAb− = NAb 
titer <1:2. All error bars are S.E.M. The legend for all panels is provided in (A).
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Figure 4. The NHP spinal cord and DRG are efficiently transduced following intrathecal AAV9 
vector administration
Four weeks following intrathecal injection of scAAV9/CBh-GFP vector, 5-7 micron 
sections from the spinal cord and DRG were subjected to IHC against GFP. Shown are 
sample images from those used for histomorphetric quantitation in Figure 3, and more 
information is available in Supplemental Figure 6 and Supplemental Table 2. These images 
are from NHP 203 and the specific areas are as follows, with spinal cord in panels A-D and 
DRG in panels E-G: (A) cervical, ventral gray matter, (B) thoracic, ventral white matter, (C) 
lumbar, dorsal gray matter, (D) lumbar, dorsal white matter, (E) cervical, (F) thoracic, and 
(G) lumbar. For each panel, the right image is a 4x enlargement of the area indicated by an 
arrow, and the total width of the right field is 55 microns. Slides are counterstained with 
cresyl violet (blue) to show nuclei, and brown (DAB) indicates GFP expression. Scale bar in 
(A) is the same for all panels and is 55 microns.
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Figure 5. The NHP brain is transduced following intrathecal AAV9 vector administration
Four weeks following intrathecal injection of scAAV9/CBh-GFP vector, 5-7 micron 
sections from the spinal cord and DRG were subjected to IHC against GFP. Shown are 
sample images from those used for histomorphetric quantitation in Figure 3A, and more 
information is available in Supplemental Figure 6 and Supplemental Table 2. These images 
are from NHP 203 brain and the specific areas are as follows: (A) brain region 1C, (B) brain 
region 2B, (C) brain region 3C, (D) brain region 4, (E) brain region 5B, (F) liver, and (G) 
spleen. For each panel, the right image is a 4x enlargement of the area indicated by an 
arrow, and the total width of the right field is 55 microns. Slides are counterstained with 
cresyl violet (blue) to show nuclei, and brown (DAB) indicates GFP expression. Scale bar in 
(A) is the same for all panels and is 55 microns.
Gray et al. Page 18













Figure 6. AAV9 strongly transduces the choroid plexus after intrathecal administration in NHPs
Four weeks following intrathecal injection of scAAV9/CBh-GFP vector, 5-7 micron 
sections were collected and subjected to IHC against GFP. The image is from NHP #206, 
block 2A (see supplemental Figure 6), with the lateral ventricle and surrounding 
parenchyma shown. Dense GFP staining is observed in virtually all of the ependymal cells 
of the choroid plexus (open arrow), no GFP seen in the ependymal cells lining the ventricles 
(closed arrow), and light GFP staining is seen in some cells within the surrounding 
parenchyma. The scale bar is 100 microns, and the inset is a 2x magnification of the area 
highlighted by the arrows.
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